4qm0 - Revision history

OCA at 12:47, 1 March 2024

OCA — Fri, 01 Mar 2024 12:47:10 GMT

←Older revision		Revision as of 12:47, 1 March 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4qm0]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QM0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4QM0 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4qm0]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QM0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4QM0 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=39K:N-(2-METHYLPROPYL)-N-({5-[4-(METHYLSULFONYL)PHENYL]THIOPHEN-2-YL}METHYL)-1-PHENYLMETHANESULFONAMIDE'>39K</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.195Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=39K:N-(2-METHYLPROPYL)-N-({5-[4-(METHYLSULFONYL)PHENYL]THIOPHEN-2-YL}METHYL)-1-PHENYLMETHANESULFONAMIDE'>39K</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4qm0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qm0 OCA], [https://pdbe.org/4qm0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4qm0 RCSB], [https://www.ebi.ac.uk/pdbsum/4qm0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4qm0 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4qm0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qm0 OCA], [https://pdbe.org/4qm0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4qm0 RCSB], [https://www.ebi.ac.uk/pdbsum/4qm0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4qm0 ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
	[https://www.uniprot.org/uniprot/RORG_HUMAN RORG_HUMAN] Possible nuclear receptor for hydroxycholesterols, the binding of which strongly promotes coactivators recruitment. Essential for thymopoiesis and the development of several secondary lymphoid tissues, including lymph nodes. Involved in lineage specification of uncommitted CD4(+) T-helper cells into Th17 cells. Regulate the expression of several components of the circadian clock.		[https://www.uniprot.org/uniprot/RORG_HUMAN RORG_HUMAN] Possible nuclear receptor for hydroxycholesterols, the binding of which strongly promotes coactivators recruitment. Essential for thymopoiesis and the development of several secondary lymphoid tissues, including lymph nodes. Involved in lineage specification of uncommitted CD4(+) T-helper cells into Th17 cells. Regulate the expression of several components of the circadian clock.
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	Using structure-based drug design principles, we identified opportunities to reduce the lipophilicity of our tertiary sulfonamide RORc inverse agonists. The new analogs possessed improved RORc cellular potencies with >77-fold selectivity for RORc over other nuclear receptors in our cell assay suite. The reduction in lipophilicity also led to an increased plasma-protein unbound fraction and improvements in cellular permeability and aqueous solubility.
-
-	Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists.,Fauber BP, Rene O, de Leon Boenig G, Burton B, Deng Y, Eidenschenk C, Everett C, Gobbi A, Hymowitz SG, Johnson AR, La H, Liimatta M, Lockey P, Norman M, Ouyang W, Wang W, Wong H Bioorg Med Chem Lett. 2014 Aug 15;24(16):3891-7. doi: 10.1016/j.bmcl.2014.06.048., Epub 2014 Jun 25. PMID:25017032<ref>PMID:25017032</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 4qm0" style="background-color:#fffaf0;"></div>
-	== References ==
-	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>

OCA at 11:35, 15 February 2023

OCA — Wed, 15 Feb 2023 11:35:21 GMT

←Older revision		Revision as of 11:35, 15 February 2023
Line 3:		Line 3:
	<StructureSection load='4qm0' size='340' side='right'caption='[[4qm0]], [[Resolution\|resolution]] 2.19Å' scene=''>		<StructureSection load='4qm0' size='340' side='right'caption='[[4qm0]], [[Resolution\|resolution]] 2.19Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4qm0]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QM0 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4QM0 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4qm0]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QM0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4QM0 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=39K:N-(2-METHYLPROPYL)-N-({5-[4-(METHYLSULFONYL)PHENYL]THIOPHEN-2-YL}METHYL)-1-PHENYLMETHANESULFONAMIDE'>39K</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=39K:N-(2-METHYLPROPYL)-N-({5-[4-(METHYLSULFONYL)PHENYL]THIOPHEN-2-YL}METHYL)-1-PHENYLMETHANESULFONAMIDE'>39K</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">RORC, NR1F3, RORG, RZRG ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4qm0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qm0 OCA], [https://pdbe.org/4qm0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4qm0 RCSB], [https://www.ebi.ac.uk/pdbsum/4qm0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4qm0 ProSAT]</span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4qm0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qm0 OCA], [~~http~~://pdbe.org/4qm0 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4qm0 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4qm0 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4qm0 ProSAT]</span></td></tr>	+
	</table>		</table>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/RORG_HUMAN RORG_HUMAN]] Possible nuclear receptor for hydroxycholesterols, the binding of which strongly promotes coactivators recruitment. Essential for thymopoiesis and the development of several secondary lymphoid tissues, including lymph nodes. Involved in lineage specification of uncommitted CD4(+) T-helper cells into Th17 cells. Regulate the expression of several components of the circadian clock.	+	[https://www.uniprot.org/uniprot/RORG_HUMAN RORG_HUMAN] Possible nuclear receptor for hydroxycholesterols, the binding of which strongly promotes coactivators recruitment. Essential for thymopoiesis and the development of several secondary lymphoid tissues, including lymph nodes. Involved in lineage specification of uncommitted CD4(+) T-helper cells into Th17 cells. Regulate the expression of several components of the circadian clock.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 23:		Line 22:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Boenig, G]]	+	[[Category: Boenig G]]
-	[[Category: Hymowitz~~, S G~~]]	+	[[Category: Hymowitz SG]]
-	[[Category: Wang, W]]	+	[[Category: Wang W]]
-	~~[[Category: Nuclear receptor ligand binding domain]]~~	+
-	~~[[Category: Transcription-transcription inhibitor complex~~]]	+

OCA at 09:28, 24 April 2019

OCA — Wed, 24 Apr 2019 09:28:35 GMT

←Older revision		Revision as of 09:28, 24 April 2019
Line 1:		Line 1:

	==Crystal structure of RORc in complex with a tertiary sulfonamide inverse agonist==		==Crystal structure of RORc in complex with a tertiary sulfonamide inverse agonist==
-	<StructureSection load='4qm0' size='340' side='right' caption='[[4qm0]], [[Resolution\|resolution]] 2.19Å' scene=''>	+	<StructureSection load='4qm0' size='340' side='right'caption='[[4qm0]], [[Resolution\|resolution]] 2.19Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4qm0]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QM0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QM0 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4qm0]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QM0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QM0 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=39K:N-(2-METHYLPROPYL)-N-({5-[4-(METHYLSULFONYL)PHENYL]THIOPHEN-2-YL}METHYL)-1-PHENYLMETHANESULFONAMIDE'>39K</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=39K:N-(2-METHYLPROPYL)-N-({5-[4-(METHYLSULFONYL)PHENYL]THIOPHEN-2-YL}METHYL)-1-PHENYLMETHANESULFONAMIDE'>39K</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">RORC, NR1F3, RORG, RZRG ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qm0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qm0 OCA], [http://pdbe.org/4qm0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4qm0 RCSB], [http://www.ebi.ac.uk/pdbsum/4qm0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4qm0 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qm0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qm0 OCA], [http://pdbe.org/4qm0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4qm0 RCSB], [http://www.ebi.ac.uk/pdbsum/4qm0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4qm0 ProSAT]</span></td></tr>
	</table>		</table>
Line 22:		Line 23:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Boenig, G]]		[[Category: Boenig, G]]
	[[Category: Hymowitz, S G]]		[[Category: Hymowitz, S G]]

OCA at 17:09, 4 January 2017

OCA — Wed, 04 Jan 2017 17:09:19 GMT

←Older revision		Revision as of 17:09, 4 January 2017
Line 1:		Line 1:
		+
	==Crystal structure of RORc in complex with a tertiary sulfonamide inverse agonist==		==Crystal structure of RORc in complex with a tertiary sulfonamide inverse agonist==
	<StructureSection load='4qm0' size='340' side='right' caption='[[4qm0]], [[Resolution\|resolution]] 2.19Å' scene=''>		<StructureSection load='4qm0' size='340' side='right' caption='[[4qm0]], [[Resolution\|resolution]] 2.19Å' scene=''>
Line 4:		Line 5:
	<table><tr><td colspan='2'>[[4qm0]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QM0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QM0 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4qm0]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QM0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QM0 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=39K:N-(2-METHYLPROPYL)-N-({5-[4-(METHYLSULFONYL)PHENYL]THIOPHEN-2-YL}METHYL)-1-PHENYLMETHANESULFONAMIDE'>39K</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=39K:N-(2-METHYLPROPYL)-N-({5-[4-(METHYLSULFONYL)PHENYL]THIOPHEN-2-YL}METHYL)-1-PHENYLMETHANESULFONAMIDE'>39K</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qm0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qm0 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4qm0 RCSB], [http://www.ebi.ac.uk/pdbsum/4qm0 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qm0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qm0 OCA], [http://pdbe.org/4qm0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4qm0 RCSB], [http://www.ebi.ac.uk/pdbsum/4qm0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4qm0 ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
Line 16:		Line 17:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4qm0" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 09:44, 5 January 2015

OCA — Mon, 05 Jan 2015 09:44:33 GMT

←Older revision		Revision as of 09:44, 5 January 2015
Line 1:		Line 1:
-	'''~~Unreleased~~ structure'''	+	==Crystal structure of RORc in complex with a tertiary sulfonamide inverse agonist==
		+	<StructureSection load='4qm0' size='340' side='right' caption='[[4qm0]], [[Resolution\|resolution]] 2.19Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[4qm0]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QM0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QM0 FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=39K:N-(2-METHYLPROPYL)-N-({5-[4-(METHYLSULFONYL)PHENYL]THIOPHEN-2-YL}METHYL)-1-PHENYLMETHANESULFONAMIDE'>39K</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qm0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qm0 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4qm0 RCSB], [http://www.ebi.ac.uk/pdbsum/4qm0 PDBsum]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/RORG_HUMAN RORG_HUMAN]] Possible nuclear receptor for hydroxycholesterols, the binding of which strongly promotes coactivators recruitment. Essential for thymopoiesis and the development of several secondary lymphoid tissues, including lymph nodes. Involved in lineage specification of uncommitted CD4(+) T-helper cells into Th17 cells. Regulate the expression of several components of the circadian clock.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Using structure-based drug design principles, we identified opportunities to reduce the lipophilicity of our tertiary sulfonamide RORc inverse agonists. The new analogs possessed improved RORc cellular potencies with >77-fold selectivity for RORc over other nuclear receptors in our cell assay suite. The reduction in lipophilicity also led to an increased plasma-protein unbound fraction and improvements in cellular permeability and aqueous solubility.

-	~~The entry 4qm0 is ON HOLD~~	+	Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists.,Fauber BP, Rene O, de Leon Boenig G, Burton B, Deng Y, Eidenschenk C, Everett C, Gobbi A, Hymowitz SG, Johnson AR, La H, Liimatta M, Lockey P, Norman M, Ouyang W, Wang W, Wong H Bioorg Med Chem Lett. 2014 Aug 15;24(16):3891-7. doi: 10.1016/j.bmcl.2014.06.048., Epub 2014 Jun 25. PMID:25017032<ref>PMID:25017032</ref>

-	~~Authors~~: Boenig, G., Hymowitz, S.G., Wang, W.	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-		+	</div>
-	~~Description~~: ~~Crystal structure of RORc in~~ complex ~~with a tertiary sulfonamide inverse agonist~~	+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Boenig, G]]
		+	[[Category: Hymowitz, S G]]
		+	[[Category: Wang, W]]
		+	[[Category: Nuclear receptor ligand binding domain]]
		+	[[Category: Transcription-transcription inhibitor complex]]

OCA: Protected "4qm0" [edit=sysop:move=sysop]

OCA — Wed, 25 Jun 2014 05:56:48 GMT

Protected "4qm0" [edit=sysop:move=sysop]

←Older revision

Revision as of 05:56, 25 June 2014

OCA: New page: '''Unreleased structure''' The entry 4qm0 is ON HOLD Authors: Boenig, G., Hymowitz, S.G., Wang, W. Description: Crystal structure of RORc in complex with a tertiary sulfonamide inverse...

OCA — Wed, 25 Jun 2014 05:56:46 GMT

New page: '''Unreleased structure''' The entry 4qm0 is ON HOLD Authors: Boenig, G., Hymowitz, S.G., Wang, W. Description: Crystal structure of RORc in complex with a tertiary sulfonamide inverse...

New page

'''Unreleased structure'''

The entry 4qm0 is ON HOLD

Authors: Boenig, G., Hymowitz, S.G., Wang, W.

Description: Crystal structure of RORc in complex with a tertiary sulfonamide inverse agonist